EXCLAIM-2 III期试验:莫博赛替尼对比含铂化疗一线治疗EGFR外显子20插入阳性转移性非小细胞肺癌
EXCLAIM-2是一项开放标签III期试验,354例初治EGFR外显子20插入阳性晚期/转移性非小细胞肺癌患者按1:1随机接受莫博赛替尼160 mg每日一次或培美曲塞联合顺铂/卡铂方案。中期分析显示两组BICR评估的中位PFS均为9.6个月(HR 1.04,95%CI 0.77-1.39,P=0.803),主要终点跨过预设无效边界,莫博赛替尼疗效未优于含铂化疗。
要点
- 莫博赛替尼组与化疗组BICR评估中位PFS均为9.6个月,HR 1.04,P=0.803,主要终点跨过预设无效边界。
- 确认ORR:莫博赛替尼32%(95%CI 26-40)vs 化疗30%(95%CI 24-38);中位缓解持续时间12.0 vs 8.4个月。
- ≥3级不良事件:腹泻(莫博赛替尼20% vs 化疗1%)、贫血(6% vs 10%)、脂肪酶升高(6% vs 0%)、中性粒细胞计数降低(1% vs 7%)。
核心结论
- EXCLAIM-2试验未达到主要终点,莫博赛替尼一线治疗EGFR外显子20插入阳性晚期/转移性非小细胞肺癌的疗效未优于含铂化疗。
研究设计与样本
- 开放标签III期试验(EXCLAIM-2,NCT04129502),比较莫博赛替尼与含铂化疗一线治疗EGFR外显子20插入阳性晚期/转移性非小细胞肺癌。
- 共354例初治患者按1:1随机分配至莫博赛替尼组(n=179)或化疗组(n=175)。
- 莫博赛替尼160 mg每日一次口服;化疗为培美曲塞联合顺铂或卡铂每3周一次共4周期后培美曲塞维持。
- 主要终点为盲法独立中心评审(BICR)评估的无进展生存期(PFS),计划在227例预期PFS事件中约70%时进行中期分析。
主要发现
- 中期分析(数据截止2023年4月4日)BICR评估中位PFS两组均为9.6个月(HR 1.04,95%CI 0.77-1.39;P=0.803)。
- 主要终点跨过预设无效边界(HR>1)。
- BICR确认客观缓解率:莫博赛替尼组32%(95%CI 26-40)vs 化疗组30%(95%CI 24-38);中位缓解持续时间12.0个月 vs 8.4个月。
- 生活质量评估显示莫博赛替尼组较化疗组在肺癌症状、认知功能和便秘的恶化时间上出现有临床意义的延迟。
- 发生率>5%的≥3级不良事件(莫博赛替尼组 vs 化疗组):腹泻(20% vs 1%)、贫血(6% vs 10%)、脂肪酶升高(6% vs 0%)、中性粒细胞计数降低(1% vs 7%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2, ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of EGFR ex20ins+ advanced/metastatic NSCLC. METHODS: Patients with treatment-naive EGFR ex20ins+ locally advanced/metastatic NSCLC were randomly assigned 1:1 to mobocertinib 160 mg once daily or pemetrexed plus cisplatin or carboplatin every 3 weeks for four cycles followed by maintenance pemetrexed. The primary end point was progression-free survival (PFS) by blinded independent central review (BICR), with planned interim analysis (IA) after approximately 70% of 227 expected PFS events. RESULTS: A total of 354 patients were randomly assigned (mobocertinib: n = 179; chemotherapy: n = 175). Baseline characteristics were balanced between arms. At IA (cutoff: April 4, 2023), the median PFS per BICR was 9.6 months in each treatment arm (hazard ratio [HR], 1.04 [95% CI, 0.77 to 1.39]; P = .803). The primary end point crossed the prespecified futility boundary (HR > 1). The confirmed objective response rate (95% CI) per BICR was 32% (26 to 40) with mobocertinib versus 30% (24 to 38) with chemotherapy; the median duration of response was 12.0 versus 8.4 months. Quality-of-life assessments indicated clinically meaningful delays in time to deterioration of lung cancer symptoms, cognitive function, and constipation with mobocertinib versus chemotherapy. Grade ≥3 adverse events in >5% of patients (mobocertinib, chemotherapy) were diarrhea (20%, 1%), anemia (6%, 10%), increased lipase (6%, 0%), and decreased neutrophil count (1%, 7%). CONCLUSION: The EXCLAIM-2 trial did not meet its primary end point. The efficacy of mobocertinib was not superior to platinum-based chemotherapy for first-line treatment of patients with EGFR ex20ins+ advanced/metastatic NSCLC.
引用
- Jänne PA, Wang BC, Cho BC, et al. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. J Clin Oncol. 2025. PMID: 39879577. doi:10.1200/JCO-24-01269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。